Leading Chemical Weapons Preparedness Companies Announce Partnership to Deploy Break-through Diagnostic Test Internationally
THE HAGUE, November 24, 2011 /PRNewswire/ –
ProQares – a leading provider of testing, evaluation and certification
services for protective equipment against chemical hazards – announced today
a partnership with U.S.-based Rapid Pathogen Screening, Inc. (RPS(R)) – a
leading developer of point-of-care diagnostic tests, to deploy ChemTox(TM)
in numerous countries throughout the European and Asia Pacific regions.
ChemTox is the first-of-its-kind point-of-care diagnostic test for human
exposure to chemical poisons in the blood, including Soman, Sarin, Tabun,
and VX, and is capable of detecting low-level chemical nerve agent exposure
in 10 minutes or less with only a simple finger-stick blood sample.
“The partnership with RPS complements ProQares’ mission to contribute to
the protection of humans against toxic threats by providing fast and
reliable test results,” said Jack van Hoof, Managing Director of ProQares.
“Through the partnership, ProQares will support RPS in marketing ChemTox to
its worldwide network of government and industrial organizations.”
“This partnership will accelerate the deployment of this break-through
technology and ensure that governments and other organizations charged with
protecting the public from a chemical weapons attack have the most
sophisticated tools available,” said Robert Van Dine, Chief IP and
Government Affairs Officer for RPS.
In June, in his address to the NATO Conference on WMD Arms Control,
Disarmament and Non-Proliferation, Ambassador Ahmet Uzuemcue,
director-general of the Organisation for the Prohibition of Chemical Weapons
(OPCW), focused NATO on his concern that “the future use of chemical weapons
in a conventional military sense is remote. The misuse, on the other hand,
of toxic chemicals, especially in an asymmetric sense, appears to be the
more likely scenario.”
A single chemical attack in an urban commercial or residential setting
can result in tens of thousands of people that require immediate diagnosis
and treatment. Treatment for chemical weapon nerve agent exposure often is
most effective within the first 40 minutes. ChemTox responds to this need by
providing a rapid, accurate and cost-effective diagnosis at the
In early 2012, RPS expects to apply the CE mark to ChemTox and begin
discussions with the U.S. Food and Drug Administration to bring it to market
in the United States. The product is not currently CE-marked and is not yet
available for sale in the United States.